The Central Drugs Standard Control Organization (CDSCO), India’s national drug regulator, has issued an advisory for pharmaceutical companies, prohibiting all direct and indirect advertising of GLP-1 receptor agonist drugs (such as Ozempic, Wegovy, and Mounjaro) to the general public.
This crackdown addresses rising concerns over the rampant misuse of these prescription-only medications for cosmetic weight loss, often fueled by unregulated social media and influencer campaigns
What are GLP-1 (glucagon-like peptide-1 receptor agonists) drugs?
- They are a class of medications designed to treat type 2 diabetes and chronic obesity by mimicking the GLP-1 hormone, which regulates blood sugar, increases satiety, and slows gastric emptying.
- Popular drugs in this class, are Ozempic, Wegovy, Mounjaro, and Saxenda.
- They were originally used for managing type 2 diabetes, but are now also used for reducing obesity andweight loss.
- Mechanism of Action: They bind to GLP-1 receptors, boosting insulin secretion (when blood sugar is high), inhibiting glucagon release, and reducing appetite by acting on the central nervous system.
- Health Benefits Beyond Diabetes/Weight: Studies indicate reduced risks of cardiovascular events (heart attack, stroke, and heart failure), chronic kidney disease progression, and potential benefits for metabolic dysfunction-associated steatotic liver disease (MASLD), and obesity-related sleep apnea.
- Side Effects: The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation.